p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas

International Journal of Gynecological Cancer

Volumn 16, Issue 2, 2006, Pages 849-853

  Anderson, S E ^a   Nonaka, D ^a   Chuai, S ^a   Olshen, A B ^a   Chi, D ^a   Sabbatini, P ^a   Soslow, R A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GYNECOLOGIC DISEASE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; UTERUS MYOMA; UTERUS TUMOR;

ADULT; AGED; DISEASE-FREE SURVIVAL; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 33646071235     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00542.x     Document Type: Article

References (26)

1. Brooks SE Zhan M Cote T Baquet CR Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999 Gynecol Oncol 2004 93 204 8
2. Buttram VC Reiter RC Uterine leiomyomata: etiology, symptomatology, and management Fertil Steril 1981 36 433 45
3. Cramer SF Patel A The frequency of uterine leiomyomas Am J Clin Pathol 1990 94 435 8
4. Okuda T Otsuka J Sekizawa A et al p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell Gynecol Oncol 2003 88 318 25
5. Geisler HE Geisler JP Miller GA et al p21 and p53 in ovarian carcinoma Cancer 2001 92 781 6
6. Geisler JP Wiemann MC Zhou S Miller GA Geisler HE p53 as a prognostic indicator in endometrial cancer Gynecol Oncol 1996 61 245 8
7. Berchuk A Dohler MF Wiseman R Boyd J Bast R The p53 tumor suppressor gene frequently is altered in gynecologic cancers Am J Obstet Gynecol 1994 170 246 52
8. Leitao MM Soslow RA Baergen RN Olvera N Arroyo C Boyd J Mutation and expression of the TP53f gene in early stage epithelial ovarian carcinoma Gynecol Oncol 2004 93 301 6
9. Nordal RR Kristensen GB Stenwig AE Trope CG Nesland JM Immunohistochemical analysis of p53 protein in uterine sarcoma Gynecol Oncol 1988 70 45 8
10. De Vos S Wilczynski SP Fleischhacker M Koeffler P p53d alterations in uterine leiomyosarcomas versus leiomyomas Gynecol Oncol 1994 54 205 8
11. Mayer TJ Frauenhoffer EE Meyers C Expression of epidermal growth factor and platelet-derived growth factor receptors during cervical carcinogenesis In Vitro Cell Dev Biol 2000 36 667 76
12. Kim JW Kim YT Kim DK Song CH Lee JW Expression of epidermal growth factor receptor in carcinoma of the cervix Gynecol Oncol 1996 60 283 7
13. Henriksen R Funa K Wilander E Backstrom T Ridderheim M Oberg K Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms Cancer Res 1993 53 4550 4
14. van Dam PA Lowe DG Watson JV et al Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract Gynecol Oncol 42 256 64
15. Matei D Chang DD Jeng MH Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation Clin Cancer Res 2004 10 681 90
16. Bell S Kempson RL Hendrickson MR Problematic uterine smooth muscle neoplasms: a clinicopathologic study of 213 cases Am J Surg Pathol 1994 18 555 8
17. Remmele W Schicketanz KH Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS) Pathol Res Pract 1993 189 862 6
18. Introduction to R Available at Accessed February 2, 2005
19. Blom R Guerrieri C Stal O Malmstrom H Simonsen E Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 49 cases Gynecol Oncol 1998 68 54 61
20. Hall K Teneriello MG Taylor RR et al Analysis of ki-ras, p53 and mdm2 genes in uterine leiomyomas and leiomyosarcomas Gynecol Oncol 1997 65 330 5
21. Zhai YL Nikaido T Orii A Horiuchi A Toki T Fujii S Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma Gynecol Oncol 1999 75 453 9
22. Amada S Nakano H Tsuney M Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins Int J Gynecol Pathol 1995 14 134 42
23. Niemann TH Raab SS Lenel JC Rodger JR Robinson RA P53 overexpression in smooth muscle tumors of the uterus Human Pathol 1995 26 375 9
24. Malstrom H Schmidt H Persson PG Carstensen J Nordenskjold B Simonsen E Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic factors Gynecol Oncol 1992 44 172 7
25. Sulzbacher I Birner P Trieb K Traxler M Land S Chott A Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma Mod Pathol 2003 16 66 71
26. Hesselager G Uhrbom L Westermark B Nister M Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model Cancer Res 2003 63 4305 9